XML 18 R5.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($)
$ in Thousands
Total
Pre Funded Warrants
Warrant
Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Pre Funded Warrants
Additional Paid-in Capital
Warrant
Accumulated Deficit
Accumulated Other Comprehensive (Loss) Income
Beginning balance (in shares) at Dec. 31, 2023       5,894,085          
Beginning balance at Dec. 31, 2023 $ 19,670     $ 59 $ 1,215,792     $ (1,196,410) $ 229
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation 1,559       1,559        
Unrealized gain on marketable securities 109               109
Net loss (11,876)             (11,876)  
Ending balance (in shares) at Mar. 31, 2024       5,894,085          
Ending balance at Mar. 31, 2024 9,462     $ 59 1,217,351     (1,208,286) 338
Beginning balance (in shares) at Dec. 31, 2023       5,894,085          
Beginning balance at Dec. 31, 2023 19,670     $ 59 1,215,792     (1,196,410) 229
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (23,679)                
Ending balance (in shares) at Jun. 30, 2024       5,904,278          
Ending balance at Jun. 30, 2024 (694)     $ 59 1,219,294     (1,220,089) 42
Beginning balance (in shares) at Mar. 31, 2024       5,894,085          
Beginning balance at Mar. 31, 2024 9,462     $ 59 1,217,351     (1,208,286) 338
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation 1,704       1,704        
Issuance of common stock under employee benefit plans, net of shares received to settle minimum tax obligation for vesting of restricted stock awards (in shares)       9,483          
Issuance of common stock under employee benefit plans, net of shares received to settle minimum tax obligation for vesting of restricted stock awards 78       78        
Stock issued during period value new issues (in shares)       19,676          
Stock issued during period value new issues 161       161        
Unrealized gain on marketable securities (296)               (296)
Net loss (11,803)             (11,803)  
Ending balance (in shares) at Jun. 30, 2024       5,904,278          
Ending balance at Jun. 30, 2024 $ (694)     $ 59 1,219,294     (1,220,089) $ 42
Beginning balance (in shares) at Dec. 31, 2024 8,487,818     8,487,818          
Beginning balance at Dec. 31, 2024 $ (5,998)     $ 85 1,233,716     (1,239,799)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation 1,164       1,164        
Issuance of stock under ESPP (in shares)       1,974,432          
Issuance of common stock under employee benefit plans, net of shares received to settle minimum tax obligation for vesting of restricted stock awards 2,222     $ 20 2,202        
Stock issued during period value new issues   $ 2,447 $ 4,174     $ 2,447 $ 4,174    
Net loss (10,616)             (10,616)  
Ending balance (in shares) at Mar. 31, 2025       10,462,250          
Ending balance at Mar. 31, 2025 $ (6,607)     $ 105 1,243,703     (1,250,415)  
Beginning balance (in shares) at Dec. 31, 2024 8,487,818     8,487,818          
Beginning balance at Dec. 31, 2024 $ (5,998)     $ 85 1,233,716     (1,239,799)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss $ (19,209)                
Ending balance (in shares) at Jun. 30, 2025 10,708,393     10,708,393          
Ending balance at Jun. 30, 2025 $ (13,986)     $ 107 1,244,915     (1,259,008)  
Beginning balance (in shares) at Mar. 31, 2025       10,462,250          
Beginning balance at Mar. 31, 2025 (6,607)     $ 105 1,243,703     (1,250,415)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation 1,135       1,135        
Issuance of stock under ESPP (in shares)       24,388          
Issuance of common stock under employee benefit plans, net of shares received to settle minimum tax obligation for vesting of restricted stock awards 77       77        
Cancellation of restricted stock awards (in shares)       (500)          
Exercise of pre-funded warrants (in shares)       222,255          
Exercise of pre-funded warrants 2     $ 2          
Net loss $ (8,593)             (8,593)  
Ending balance (in shares) at Jun. 30, 2025 10,708,393     10,708,393          
Ending balance at Jun. 30, 2025 $ (13,986)     $ 107 $ 1,244,915     $ (1,259,008)